Health institutions, such as diagnostic laboratories, have the possibility to manufacture and use the WID®-easy tests in accordance with Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) Article 5 (5) or corresponding national regulations.

The necessary scientific and technical information can be found in the published literature, in particular Evans et al, The Lancet Oncology, 2023.

In January 2023, the Medical Device Coordination Group (MDCG) published the“Guidance on the health institution exemption under Article 5 (5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746“, which clarifies and comments on key aspects of the regulatory basis.

Diagnostic laboratories can obtain all necessary reagents for the production and use of the test from relevant suppliers.

To simplify logistics, healthcare facilities can obtain a set of reagents required to carry out the PCR reaction from Sola Diagnostics GmbH as an RUO PCR kit (“WID®-easy PCR Kit”).

The legal manufacturer of the RUO WID®-easy PCR Kit is Sola Diagnostics GmbH. The PCR kit was developed, verified and manufactured in accordance with ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes, in collaboration with a renowned German contract manufacturer that has been active for over 20 years.

Sola Diagnostics GmbH provides the WID®-easy PCR Kit to health institutions at a cost price with no profit margin.

The performance and marketing of the WID®-easy test are subject to the intellectual property rights of University College London (“UCL”) and Sola Diagnostics GmbH.

“WID” is a registered trademark of Sola Diagnostics GmbH.

The rights to perform and market the WID®-easy test can be acquired from Sola Diagnostics GmbH as a license or sublicense (in the case of UCL rights). The licensing fee is calculated based on the number of reports billed by the health institution.